Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lexaria Bioscience Corp 740 McCurdy Road No. 100 Kelowna BC V1X 2P7 CAN

https://www.lexariabioscience.com P: 250-765-6424

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Key Statistics

Overview:

Market Capitalization, $K 42,270
Shares Outstanding, K 5,104
% of Institutional Shareholders 1.39%

Financials:

Annual Sales, $ 706 K
Annual Net Income, $ -11,902 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,595 K

Growth:

1-Year Return -21.13%
3-Year Return -88.48%
5-Year Return 75.00%
5-Year Revenue Growth 12.92%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.86
EPS Growth vs. Prev Year 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 01/12/21

LXX.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -146.97%
Return-on-Assets % -136.24%
Profit Margin % -1,686.00%
Debt/Equity 0.03
Price/Sales 28.56
Price/Book 2.99
Book Value/Share 2.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar